Sign InCassava Sciences Stock Plummets 83.78% Amid Failed Alzheimer’s Drug Trials and Legal Woes
Summary
As of November 25, 2024, Cassava Sciences, Inc. (NASDAQ: SAVA) has plummeted 83.78% to $4.30, nearing its 52-week low, amid panic selling and negative sentiment following failed trial results for its Alzheimer’s drug and ongoing legal investigations, positioning the stock as a 'Sell' candidate amidst a backdrop of substantial risk and uncertainty.
Technical Analysis
Cassava Sciences, Inc. (NASDAQ: SAVA) experienced a significant decline in stock price, closing at $4.30 on November 25, 2024, representing a dramatic drop of 83.78%. The stock is trading near its 52-week low of $3.70, a stark contrast from its 52-week high of $42.20. The elevated trading volume of 93.30 million shares against an average of 1.77 million suggests high investor activity and likely panic selling.
The Relative Strength Index (RSI) of 29 indicates that the stock is currently in oversold territory, hinting at potential short-term technical relief. However, the 50-day and 200-day moving averages of $27.56 and $22.96, respectively, suggest that the stock is significantly below its medium-to-long-term trend, underscoring bearish sentiment.
MACD readings also reflect a negative momentum, and the lack of clear support and resistance levels further exacerbates the uncertainty surrounding the stock. The significant drop in price volatility, with an ATR of 96.30, indicates potential continued instability in the near term.
Fundamental Analysis
Fundamentally, Cassava Sciences is facing severe challenges. The company’s market capitalization stands at approximately $206.63 million, reflecting diminished investor confidence following the unsuccessful Phase 3 results of its Alzheimer’s drug, simufilam. The DCF model values the company at $2.89, below its current trading price, indicating that the stock may still be overvalued based on expected future cash flows.
Cassava Sciences reported an EPS of -$1.38 and a negative P/E ratio of -3.11, highlighting unprofitability and potential financial distress. The upcoming earnings announcement on February 26, 2025, may provide further insights into the company’s financial health and any strategic pivot post-study results.
Intrinsic Value and Long-term Investment Potential
The intrinsic value of Cassava Sciences appears frail due to its reliance on the success of its drug in development, which has now met a major setback. As the drug did not meet critical efficacy endpoints, this raises questions about the pipeline's viability and the company's capacity to generate future revenue. Long-term investment potential is clouded by these uncertainties and the ongoing legal investigations, which could incur further financial liabilities.
Market Sentiment and Evaluation
The recent news of investigations launched by law firms and the negative coverage of failed Phase 3 trial results have created a bearish atmosphere surrounding the stock. Despite some analysts maintaining a 'buy' consensus, reflecting potential hope for recovery or a turnaround, current conditions suggest a cautious stance. Social sentiment, as driven by influential figures such as Martin Shkreli, might pressure the stock further in the short term.
Overall, Cassava Sciences is classified as a 'Sell' candidate due to its severe technical breakdown, diminishing fundamental prospects, and impending legal investigations that add to the risk profile. Short-term volatility may create tradable opportunities, but long-term investors should consider the heightened risks and uncertainties involved with the stock at this juncture.
